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Abstract
AIM: To outline the feasibility, safety, adverse events 
and early results of endoscopic ultrasound (EUS)-
radiofrequency ablation (RFA) in pancreatic neoplasms 
using a novel probe. 
METHODS: This is a multi-center, pilot safety feasibility 
study. The intervention described was radiofrequency 
ablation (RF) which was applied with an innovative 
monopolar RF probe (1.2 mm Habib EUS-RFA catheter) 
placed through a 19 or 22 gauge fine needle aspiration 
(FNA) needle once FNA was performed in patients with 
a tumor in the head of the pancreas. The Habib™ EUS-
RFA is a 1 Fr wire (0.33 mm, 0.013”) with a working 
length of 190 cm, which can be inserted through 
the biopsy channel of an echoendoscope. RF power 
is applied to the electrode at the end of the wire to 
coagulate tissue in the liver and pancreas.
RESULTS: Eight patients [median age of 65 (range 
27-82) years; 7 female and 1 male] were recruited in a 
prospective multicenter trial. Six had a pancreatic cystic 
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Clinical Trials Study
neoplasm (four a mucinous cyst, one had intraductal 
papillary mucinous neoplasm and one a microcystic 
adenoma) and two had a neuroendocrine tumors (NET) 
in the head of pancreas. The mean size of the cystic 
neoplasm and NET were 36.5 mm (SD ± 17.9 mm) 
and 27.5 mm (SD ± 17.7 mm) respectively. The EUS-
RFA was successfully completed in all cases. Among 
the 6 patients with a cystic neoplasm, post procedure 
imaging in 3-6 mo showed complete resolution of 
the cysts in 2 cases, whilst in three more there was a 
48.4% reduction [mean pre RF 38.8 mm (SD ± 21.7 
mm) vs  mean post RF 20 mm (SD ± 17.1 mm)] in size. 
In regards to the NET patients, there was a change 
in vascularity and central necrosis after EUS-RFA. No 
major complications were observed within 48 h of the 
procedure. Two patients had mild abdominal pain that 
resolved within 3 d. 
CONCLUSION: EUS-RFA of pancreatic neoplasms with 
a novel monopolar RF probe was well tolerated in all 
cases. Our preliminary data suggest that the procedure 
is straightforward and safe. The response ranged from 
complete resolution to a 50% reduction in size. 
Key words: Endoscopic ultrasound; Radiofrequency 
ablation; Pancreas; Cystic neoplasms; Neuroendocrine 
tumors
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This manuscript presents a pilot, safety 
feasibility study with the results of the first in humans 
endoscopic ultrasound (EUS) guided radiofrequency 
ablation (RFA) for cystic neoplasms and neuroendocrine 
tumors of the pancreas with a novel EUS-RFA catheter. 
EUS-RFA is feasible and well tolerated. EUS-RFA with 
this novel catheter provides endoscopic treatment 
option other than surgical resection for pancreatic 
lesions.
Pai M, Habib N, Senturk H, Lakhtakia S, Reddy N, Cicinnati 
VR, Kaba I, Beckebaum S, Drymousis P, Kahaleh M, Brugge 
W. Endoscopic ultrasound guided radiofrequency ablation, for 
pancreatic cystic neoplasms and neuroendocrine tumors. World J 
Gastrointest Surg 2015; 7(4): 52-59  Available from: URL: http://
www.wjgnet.com/1948-9366/full/v7/i4/52.htm  DOI: http://
dx.doi.org/10.4240/wjgs.v7.i4.52
INTRODUCTION
Incidental pancreatic solid or cystic lesions are diagnosed 
with increased frequency due to the widespread use 
of abdominal cross-sectional imaging to investigate 
unrelated symptoms. In a large single-centre study, 
pancreatic cysts were diagnosed in 1.2% of 24000 
individuals subjected to abdominal cross-sectional 
imaging[1]. As a result, the majority of these lesions 
are diagnosed at an earlier stage, before they become 
invasive and present with jaundice, pancreatitis or 
abdominal pain[2]. Lesions such as neuroendocrine 
tumors (NET), mucinous cystadenomas and intraductal 
papillary mucinous neoplasms have the potential of 
malignant transformation. This risk is lower with NET, 
but significantly higher with mucinous lesions[3]. 
The standard treatment of solid or cystic pancreatic 
lesions with malignant potential has been surgical 
resection, with lesions in the pancreatic head requiring 
a Whipple resection whereas pancreatic tail lesions 
are treated with distal pancreatectomy. Both types 
of resection carry significant morbidity and mortality, 
resulting in unacceptably high risk/benefit ratios for 
many elderly patients with co-morbidities[4,5]. Currently, 
patients deemed unfit for major pancreatic surgery are 
offered cross-sectional imaging surveillance at regular 
intervals according to the International Association of 
Pancreatology Guidelines[6]; these guidelines recommend 
annual imaging for lesions < 10 mm, 6-monthly 
imaging for cysts 10-20 mm and 3-monthly imaging 
for lesions larger than 20 mm. However, controversy 
exists regarding the optimal follow up of patients with 
primary pancreatic lesions, underlying the need for 
minimally invasive ablative techniques as alternative to 
surgical resection. 
Radiofrequency ablation (RFA) has been used 
percutaneously and intraoperatively to treat primary and 
secondary liver cancers by achieving localized tumor 
necrosis[7-10]. Endo-biliary application of radiofrequency 
(RF) has been developed in our unit and used in 
patients with inoperable bile duct and pancreatic head 
adenocarcinomas presenting with biliary obstruction[11]. 
Many alternative techniques of endoscopic ultrasound 
(EUS)-guided tumor ablation have been described, 
including RF ablation, photodynamic therapy, laser 
ablation, and ethanol injection[12]. 
EUS-RFA could achieve complete ablation of pan-
creatic cysts with malignant potential in patients unfit 
for surgery, thus eliminating the requirement for long-
term surveillance in this group of individuals. Gaidhane 
et al[13] showed that EUS-RFA of the pancreatic head 
using Habib EUS-RFA catheter (Emcision Ltd., United 
Kingdom) through a 19 gauge needle was well tolerated 
in 5 Yucatan pigs with minimum amount of pancreatitis. 
The aim of this study is to outline the safety, feasibility, 
adverse events and early results of EUS-RFA in patients 
with pancreatic neoplasms using a novel probe.
MATERIALS AND METHODS
Patients
Eight patients were subjected to EUS-RFA of a 
neoplastic lesion in the head of the pancreas. A novel 
monopolar RF catheter [Habib™ EUS-RFA catheter, 
Emcision Ltd., London (CE Marked)] (Figure 1) was 
placed through a 19 or 22 gauge fine needle aspiration 
(FNA) needle. 
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introduced into the target lesion. In pancreatic cystic 
lesions, effort was made to completely aspirate the 
cyst before applying RFA. The tip of the needle was 
positioned near the far end of the lesion. In case of 
pancreatic NET also, the FNA needle was positioned at 
the deepest part of the tumor. The stylet is removed 
from the biopsy needle and Habib™ EUS RFA catheter 
is gently pushed inside the hollow of the biopsy 
needle until it cannot be pushed any further. Carefully 
maintaining this position of the Habib™ EUS RFA 
probe, the FNA needle is gradually withdrawn by 3 cm 
in order to disengage contact between the active part 
of the RF catheter located at the tip and the metallic 
FNA needle. Fluoroscopy assists in visualization of the 
RFA probe protruding beyond the tip of the needle 
(Figure 2). The tip of the probe is floppy, and may take 
a curved shape in emptied cystic lesons.
RF energy is applied for 90-120 s at the set 
wattage. In larger lesions, the Habib™ EUS RFA probe 
and needle is pulled back as one unit and repositioned 
to ablate near end of the lesion (Figures 3-5). This 
process can be repeated as many times, as needed 
to ensure complete ablation of the lesion. In larger 
pancreatic lesions, repeat puncture with the FNA 
needle is done in a different axis (after withdrawing 
the RFA probe, with or without replacing with stylet). 
The patients were managed post procedure as per 
standard hospital practice for EUS interventional 
procedures.
RESULTS 
Eight patients [median age of 65 (range 27-82) years; 
7 female and 1 male] were recruited in a prospective 
multicentre trial. Six had a pancreatic cystic neoplasm 
(four a mucinous cyst, one had IPMN and one a 
microcystic adenoma). In all six cases, diagnosis was 
based on imaging reviewed by an expert radiologist. 
The remaining two cases, had a NET in the head of 
pancreas (previously documented with diagnostic FNA 
cytology and not suitable for surgical intervention). 
The mean size of the cystic neoplasms and NETs were 
Inclusion criteria were age over 18 years, patients 
with a cystic pancreatic lesions that were not suitable 
surgical candidates and patients that consented to 
participate in the study. Exclusion criteria included 
patients younger than 18 years, patients not consenting 
to participate in the study, uncorrected coagulopathy 
and cardiac pacemakers in situ.
All patients were investigated with blood tests; 
haematological, biochemical, tumor markers as well 
as radiological investigation including computed 
tomography scan and ultrasound scans. On follow-up, 
patients had clinical examination, blood tests and cross 
sectional imaging to assess the pancreatic lesion. The 
follow-up ranged from 3 to 6 mo. Data are presented 
as mean plus or minus standard deviations of the 
mean or median with range. Research was carried out 
in accordance with the Helsinki Declaration.
Description of device
The Habib™ EUS-RFA is a 1 Fr wire (0.33 mm, 0.013”) 
with a working length of 190 cm, which can be inserted 
through the biopsy channel of an echoendoscope. RF 
power is applied to the electrode at the end of the wire 
to coagulate tissue in the liver and pancreas. This is 
a monopolar device and is used in conjunction with a 
patient grounding/diathermy pad.
Intervention
Habib™ EUS-RFA catheter comes in a dispensing 
sheath. The catheter is removed from the dispensing 
sheath and connected to the adaptor cable, which 
is then connected to the generator. Power in the 
generator is set to the required wattage we used 5-25 
Watts in our patient group). A patient grounding/
diathermy pad is applied as close to the operating 
field as possible, since the catheter is monopolar. We 
applied the pad on the lower back of the patient. The 
entire area of the grounding pad should be reliably 
applied to the patient’s body to avoid skin burns. 
The echoendoscope is manoeuvred to obtain proper 
sonographic visualization of the target lesion. Under 
EUS control, a 19 gauge biopsy needle (with stylet) is 
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Uncoated electrode
PTFE coated stainless steel shaft
COOK EchoTip needle with U/S surface
Figure 1  Close up of the HabibTM endoscopic ultrasound-radiofrequency 
ablation catheter showing uncoated electrode at the tip and the PTFE 
Coated stainless steel shaft.
Figure 2  Fluoroscopic view of HabibTM endoscopic ultrasound-radiofrequency 
ablation catheter (black arrow) protruding out of the endoscopic ultrasound 
Biopsy needle (white arrow).
36.5 mm (SD ± 17.9 mm) and 27.5 mm (SD ± 17.7 mm) respectively. RF [Rita (Model 1500X) or ERBE 
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A B
C D
Figure 3  Endoscopic ultrasound pictures of radiofrequency 
ablation of pancreatic cyst. A: Pancreatic cyst with the biopsy 
needle in position; B: Aspiration of the pancreatic cyst; C and 
D: Complete aspiration of the cyst followed by radiofrequency 
ablation using the endoscopic ultrasound radiofrequency 
ablation catheter.
A B
Figure 4  Endoscopic ultrasound Pictures of radiofrequency ablation of pancreatic cyst. A: Pancreatic cyst Pre ablation (arrow); B: Pancreatic cyst aspirated 
completed and the radiofrequency ablation with in process using the endoscopic ultrasound radiofrequency ablation catheter (arrow).
A B
Figure 5  Endoscopic ultrasound radiofrequency ablation of pancreatic neuroendocrine tumors. A and B: Endoscopic ultrasound pictures of the pancreatic 
neuroendocrine tumors pre and during ablation.
(Model ICC 200) was applied at 5 watts, 15 watts, 20 
watts and finally 25 watts in 3, 2, 2 and one patients 
respectively over 90 s for each watt setting (Table 1). 
The median number of applications was 4.5 (range 
2-7). Patients with cystic neoplasm and one patient 
with NET had one session of RFA each, whilst a second 
patient with NET had two sessions of RFA. 
The EUS-RFA was completed in all cases. Amongst 
the 6 patients with pancreatic cystic neoplasm, the 
post procedure imaging in 3-6 mo showed complete 
resolution of the cysts in 2 patients, whilst in 3 patients 
there was 48.4% reduction [mean pre RF 38.8 mm (SD 
± 21.7 mm) vs mean post RF 20 mm (SD ± 17.1 mm)] 
in size (Table 2). Using cross sectional imaging in 2 
patients with NET, a change in vascularity and central 
necrosis after EUS-RFA was demonstrated. There 
were no episodes of post-procedural pancreatitis, 
perforation or bleeding within 48 h. Two patients had 
mild abdominal pain that resolved in 3 d. 
DISCUSSION
RFA is a well-recognized, safe and effective modality 
for the treatment of focal malignant diseases[14,15]. RFA 
uses high-frequency alternating current to generate 
thermal energy and thus coagulative necrosis to 
the tissue[16]. The technique is minimally invasive 
and has very good tolerability which are the major 
advantages[17]. RFA is increasingly applied in pancreatic 
lesions[18], including unresectable pancreatic carcinoma 
where RFA has an acceptable mortality but high 
morbidity[16,17,19-21]. In general, adverse events are 
associated with the duration of ablation. Pancreas is 
very thermo-sensitive, and when heat is applied on 
normal pancreas it produces an inflammatory response 
causing edema and later fibrosis and occasionally 
cystic transformation[18]. Massive necrosis of the 
pancreas following RFA have been reported, probably 
due to sequential ablations done in close proximity at 
the same session[17,20]. 
In recent years there have been reports of pro-
spective studies using RFA in locally advanced 
pancreatic adenocarcinoma. In 2010, Girelli et al[22] 
reported ultrasound-guided RFA during laparotomy in 
fifty patients with locally advanced pancreatic cancer. 
In this prospective study the main outcome measures 
were short-term morbidity and mortality. In thirty four 
patients the tumor was located in the pancreatic head 
or the uncinate process and in 16 in the body or tail; 
median diameter was 40 (inter-quartile range 30-50) 
mm. Abdominal adverse events occurred in 24% of 
patients. Half of those were directly associated with 
RFA (two pancreatic fistulas and four cases of portal 
vein thrombosis) and were managed conservatively. 
When the applied heat was reduced from 105 degrees 
C to 90 degrees C there was a significant reduction in 
adverse events (ten vs two of 25 patients; P = 0.028). 
Median postoperative hospital stay was 10 (range 
7-31) d. The authors concluded that RFA of locally 
advanced pancreatic cancer is feasible and relatively 
well tolerated. In another observational study, the 
same group compared patients with locally advanced 
pancreatic carcinoma treated with either primary RFA 
(group 1) or RFA following any other primary treatment 
(group 2)[23]. In total, 107 consecutive patients were 
treated with RFA of which 47 patients in group 1 and 60 
in group 2. Median overall survival was 25.6 mo and it 
was significantly shorter in group 1 than in group 2 (14.7 
mo vs 25.6 mo; P = 0.004). In this study the authors 
reported that RFA after alternative primary treatment 
was associated with prolonged survival. 
RFA has been proposed by many groups as a 
strong adjuvant for antitumor response as it induces 
an immune response targeting tumor antigens[24-26]. 
In situ tumor destruction by RFA provides the immune 
system with an antigen for the induction of antitumor 
immunity. Antigen-presenting cells take up antigens 
in the periphery after which they induce specific 
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Table 1  Patient characteristics and procedure specifications
Age Sex Diagnosis No. of RF 
applications/session
No of 
sessions 
Dead/
alive
5 Watts
  82 F Mucinous cyst 3 1 Alive
  73 F Mucinous cyst 5 1 Alive
  46 F Microcystic 
adenoma 
5 1 Alive
15 Watts
  40 F Mucinous cyst 3 1 Alive
  27 F Mucinous cyst 2 1 Alive
20 Watts
  57 F NET 6 1 Alive
  82 F NET 4 2 Alive
25 Watts
  78 M IPMN 7 1 Alive
IPMN: Intraductal papillary mucinous neoplasm; NET: Neuroendocrine 
tumors; RF: Radiofrequency; F: Female; M: Male.
Table 2  Outcome after endoscopic ultrasound radiofrequency 
ablation of pancreatic cystic neoplasm and neuroendocrine tumors
No. Diagnosis Pre ablation 
size (mm) 
Post ablation size 
(mm) 
Adverse 
events
1 Mucinous cyst 30 10 No 
2 Mucinous cyst 40 Cyst not seen No 
3 Microcystic 
adenoma
20 8 No 
4 Mucinous cyst 70 45 Mild pain 
5 Mucinous cyst 24 Cyst not seen Mild pain 
6 IPMN 35 17 No 
7 NET 15 Change in 
vascularity 
No 
8 NET 40 Central area of 
necrosis 15 mm 
No 
IPMN: Intraductal papillary mucinous neoplasm; NET: Neuroendocrine 
tumors.
immune responses[25]. Wissniowski et al[24] reported 
that RFA can induce a tumor-specific T-cell reaction 
in the non-reactive neoplasm-bearing host, probably 
by overcoming immune tolerance and leading to the 
presentation of otherwise cryptic neoplastic antigens. 
In another study, ablation of hepatocellular carcinoma 
(HCC) was found to induce a functional transient 
activation of myeloid dendritic cells associated with 
increased serum levels of TNF-α and IL-1b with a 
sustained antitumoral immune response[26]. Moreover, 
animals treated with subtotal RF ablation showed 
significant increases in tumor-specific class Ⅰ and 
Ⅱ responses to male minor histocompatibility (HY) 
antigens and tumor regression[27]. Subtotal RF ablation 
produces an enhanced systemic antitumor immune 
response and tumor regression which is related to 
increased dendritic cell infiltration. RFA can also induce 
a tumor-specific proliferative T cell response and even 
transplantable protective immunity[28].
Intraoperative RFA uses a larger device with higher 
energy and is associated with significant morbidity 
and mortality. However, EUS guided RFA is a more 
conservative approach and avoids surgical intervention. 
Goldberg et al[29] applied EUS guided RFA to the 
pancreas of 13 Yorkshire pigs at 285 ± 120 mA for 6 
min resulting in discrete zones of coagulation necrosis 
in the porcine pancreas. Only one of the 13 animals had 
increased lipase levels and mild focal pancreatitis. No 
other significant adverse events were observed. A more 
recent study in 2008 demonstrated the feasibility and 
efficacy of EUS RFA using a newly developed bipolar 
ablation probe combining RFA and cryotechnology in 14 
pigs. The size of the ablation achieved was related to the 
duration of ablation; when applied for 900 s there was a 
high complication rate in the healthy pancreas. Adverse 
events were less common compared to conventional 
RFA needles[18]. In a recent study by Kim et al[30], EUS-
RFA of the pancreas was applied on 10 adult mini pigs. 
An 18 gauge endoscopic RFA probe was used to ablate 
the body and tail of the pancreas, with an output power 
of 50 W for 5 min. On histology, there was a spherical 
necrotic lesion surrounded by fibrous tissue localized 
in the pancreatic parenchyma. The mean diameter 
of the ablated tissue was 23.0 ± 6.9 mm. No major 
procedure-related adverse events were observed, and 
all pigs survived without any distressed behavioural 
pattern for 7 d until autopsy. Another minimally invasive 
technique for treatment of pancreatic cystic lesions with 
moderate success is the EUS-guided injection of ethanol 
into the cyst, with reported efficacy of 33.5%-62% 
in achieving cyst resolution[31,32]. The adverse events 
associated with this technique are significant, with 
a reported risk of severe post-procedural pain and 
pancreatitis of 4%-20%. Also, the presence of multiple 
septations within the cyst reduces the efficacy of 
ethanol injection. Another limitation of ethanol ablation 
is that this method would not be suitable for treatment 
of solid pancreatic lesions. A major potential advantage 
of EUS-RFA of cystic tumors is that it could be done in 
a minimally invasive way, with the likelihood of fewer 
adverse events than the alcohol injection because the 
area of ablation can be assessed and monitored in real-
time by EUS.
EUS-RFA using Habib EUS-RFA catheter (Emcision 
Ltd., United Kingdom) through a 19 gauge needle 
for ablation of lymphatic and pancreatic tissue, was 
reported in two animal studies. In the former study[33], 
EUS-guided RFA ablation of mediastinal lymph nodes 
was successfully attempted in six pigs. RFA was 
performed with the ERBE Vaio generator (ERBE, 
Tuttlingen, Germany) with bipolar settings of 10 watts, 
effect 2 for 2 min. During the procedure, the probe 
was visible in all cases. No evidence of ablation effect 
in the surrounding tissue or at the needle puncture site 
was seen on gross examination. There was a direct 
correlation between the probe length and the size 
of necrosis. In the pancreatic study using the same 
catheter, five Yucatan pigs underwent EUS-guided RFA 
of the head of the pancreas[13]. RFA was applied with 
6 mm of the probe exposed at 4 watts for 5 min, 5 
watts for 0.9 min, and 6 watts for 0.2 min. Then, with 
10 mm of the probe exposed in the pancreas, RFA was 
performed at 4 watts for 4.3 min, 5 watts for 1.4 min, 
and 6 watts for 0.8 min. Autopsy showed moderate 
level of pancreatitis, with involvement of 20% of the 
proximal pancreatic tissue in only one pig. There was 
minimal tissue damage in the other animals. In this 
study EUS-guided RFA of the pancreatic head with the 
monopolar probe through a 19 gauge needle was well 
tolerated with a minimal amount of pancreatitis. 
We have reported in this prospective study the 
application of RFA via the novel Habib EUS-RFA 
catheter (Emcision Ltd., United Kingdom) for pancreatic 
cystic neoplasms and NET. The concept of treating 
pre-malignant asymptomatic pancreatic lesions by 
means other than surgical resection is appealing, as 
the latter is associated with major morbidity and some 
mortality. This study shows that such an approach 
is feasible and safe. Our patients were discharged 
hours without any major adverse events. However, it 
is conceivable that the application of RF energy in the 
pancreatic parenchyma may be associated with some 
adverse events. Such adverse events may include 
(but not necessarily limited to) acute pancreatitis, 
pancreatic leaks, infection of necrotic pancreatic tissue 
post treatment and bleeding. Using lower energy also 
allows for repeating the ablation with low morbidity 
as per clinical indication. EUS-RFA of pancreatic 
neoplasms with a novel monopolar RF probe was well 
tolerated in all patients. These preliminary data results 
suggest that the procedure is technically easy and 
safe. The response ranged from complete resolution 
to a 50% reduction in diameter. Further multicenter 
experience is required before widespread use of this 
novel procedure.
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This first in human study shows that EUS-RFA with this novel catheter provides 
an endoscopic treatment option other than surgical resection for pancreatic 
lesions.
Innovations and breakthroughs
The standard treatment of solid or cystic pancreatic lesions with malignant 
potential has been surgical resection. Pancreatic resections carry significant 
morbidity and mortality, resulting in unacceptably high risk/benefit ratios for 
many elderly patients with co-morbidities. There is an unmet need for minimally 
invasive ablative techniques as alternative to surgical resection.
Applications
Our results show that the procedure is technically easy and safe. The response 
in this series ranged from complete resolution to a 50% reduction in diameter. 
Therefore it might be an excellent alternative for patients that are not suitable 
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Terminology
Radiofrequency ablation is the procedure of destructing tissue with the use of heat 
generated from high frequency alternating current (in the range of 350-500 kHz). It is 
a widely accepted method of tissue destruction for primary solid organ tumors. 
It has been used in the management of primary liver and lung tumors in patients 
that are not suitable surgical candidates and in secondary malignancies as part 
of the treatment algorithm. 
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